A DMD diagnosis usually starts with a quiet worry: a 3-year-old who can't keep up with peers, falls a lot, climbs stairs one foot at a time, and pushes his hands up his thighs to stand (the Gowers' manoeuvre). A GP runs bloods, the creatine kinase comes back ten or twenty times the normal range, and a genetic test confirms it. For most families, the name arrives long before the understanding does.
What that name means today is genuinely different from what it meant twenty years ago. DMD is still serious and progressive, but corticosteroids, cardiac and respiratory monitoring, and a growing set of mutation-specific therapies have changed the trajectory. Boys diagnosed now typically walk longer, breathe better, and live much further into adulthood than the generation before them. Healthbooq covers complex paediatric conditions like DMD; for broader context see our complete guide to child health.
The Biology
DMD is caused by mutations in the dystrophin gene on the X chromosome — one of the largest genes in the human genome. Dystrophin acts as a shock absorber inside muscle cells, anchoring the contractile machinery to the surrounding membrane. Without it, every contraction does a little damage. Over years, muscle is replaced by fat and scar tissue.
Because the gene is X-linked recessive, DMD almost exclusively affects boys. Female carriers usually have no or only mild symptoms. About a third of cases come from new mutations, with no family history at all — so an out-of-the-blue diagnosis does not mean a parent missed something.
Mutation type matters. Most DMD mutations are deletions that disrupt the reading frame and abolish dystrophin entirely. Becker muscular dystrophy is a milder cousin: the same gene, but in-frame mutations that allow some partial dystrophin to be made. Knowing the exact mutation also determines eligibility for newer mutation-specific drugs.
Signs and Progression
First signs typically show up between 2 and 5 years old:
- Walking later than expected, often after 18 months
- Waddling gait, frequent falls, trouble running
- Difficulty with stairs and getting up off the floor
- Gowers' manoeuvre — pushing hands up the thighs to stand
- Calves that look unusually large but are actually weak (pseudohypertrophy)
- Markedly elevated creatine kinase on bloods
Without treatment, most boys lose the ability to walk somewhere between ages 8 and 12. Scoliosis tends to develop after that. The heart muscle is also affected — dilated cardiomyopathy usually starts to show in the early teens — and respiratory muscles weaken over time, eventually requiring non-invasive ventilation. Learning differences are somewhat more common than in the general population, because dystrophin is also expressed in the brain.
Standard of Care
The backbone of DMD treatment is daily corticosteroids — prednisolone or deflazacort — usually started in the early primary school years. Multiple randomised trials, including long-running work by Craig McDonald and the CINRG group, show that steroids slow muscle decline, extend independent walking by roughly 2 to 3 years, delay scoliosis, and protect heart and lung function. Side effects (weight gain, growth slowing, bone density, behaviour) are real and managed actively by the team.
Cardiac care is the second pillar. ACE inhibitors and beta-blockers are typically started early, often before symptoms appear, with regular echocardiograms and cardiac MRI. This early protective approach is one of the biggest reasons life expectancy has shifted upward.
The third is respiratory. As forced vital capacity falls, non-invasive ventilation (BiPAP) is introduced — first at night, later extended as needed. Respiratory support is the single change that has done the most to push median survival from the late teens into the thirties and beyond.
Physiotherapy and occupational therapy run alongside throughout: stretching to delay contractures, splinting, wheelchair fitting when ambulation ends, home and school adaptations.
Newer Therapies
Since around 2016, the therapeutic landscape has shifted. None of these are cures, but they expand what's possible.
Exon-skipping drugs (eteplirsen, golodirsen, viltolarsen, casimersen) use antisense oligonucleotides to make the ribosome skip a specific mutated exon, allowing production of a shortened but partly functional dystrophin. They only work for boys whose mutation matches the targeted exon — together they cover roughly 30% of the DMD population. They are FDA-approved; NHS access via NICE has been more limited because of debate over the size of the clinical benefit.
Gene therapy delivers a miniature dystrophin gene (micro-dystrophin) via an adeno-associated viral vector. Delandistrogene moxeparvovec (Elevidys) received conditional FDA approval in 2023; eligibility, durability, and UK availability are still evolving and worth discussing in detail with your specialist team.
CRISPR-based gene editing and utrophin upregulation (utrophin is a structural cousin of dystrophin) are earlier in development. Trial enrolment is the route to access for most of these, and specialist centres can flag what your child's mutation makes them eligible for.
In the UK, Francesco Muntoni's group at UCL Great Ormond Street Institute of Child Health runs one of the largest European DMD research programmes and is a useful reference point for what's coming.
Multidisciplinary Care
DMD care is a team sport. A typical clinic loop involves:
- Paediatric neurologist or neuromuscular specialist (overall coordination)
- Cardiologist (annual or more frequent monitoring)
- Respiratory team (lung function, sleep studies, ventilation)
- Physiotherapy and occupational therapy (movement, contractures, equipment)
- Orthopaedics (scoliosis surveillance and surgery if needed)
- Endocrinology and dietetics (steroid side-effect management, bone health, growth)
- Educational psychology and school liaison
In the UK, specialist neuromuscular services at Great Ormond Street, Alder Hey, Newcastle, and other regional centres coordinate this care through the North Star network. Muscular Dystrophy UK is the main UK charity providing information, family support, and connection to the wider DMD community. Treat-NMD and the Muscular Dystrophy Association are useful international references.
What to Ask Your Team
A few questions worth raising at clinic, especially in the first year after diagnosis:
- What is my son's exact mutation, and what does it make him eligible for now and in trials?
- When will we start steroids, and what is the plan for side-effect monitoring?
- What is the baseline cardiac and respiratory schedule?
- Which trials are recruiting at our centre or by referral?
- What support is available for siblings, school, and us as parents?
The diagnosis is heavy. The trajectory is genuinely better than it used to be, and a coordinated team — plus a charity like Muscular Dystrophy UK — can take a real share of the load.
Key Takeaways
Duchenne muscular dystrophy (DMD) is an X-linked condition affecting roughly 1 in 3,500 to 5,000 boys, caused by mutations in the dystrophin gene. First signs usually appear between ages 2 and 5. With corticosteroids and current cardiac and respiratory care, most boys now keep walking into their teens and live well into their thirties — a substantial change from a generation ago. Newer exon-skipping and gene therapies apply to specific mutations and are evolving quickly.
